Casi Pharmaceuticals Inc Stock Price, News & Analysis

CASI Pharmaceuticals, a U.S. biopharmaceutical company, announced that Dr. Wei-Wu He, Chairman and CEO, will present at the H.C. Wainwright Bioconnect Conference on January 11, 2021, at 6:00 AM (ET). This virtual event will feature a webcast available on CASI's website under 'Events & Presentations', with archived replays accessible for 90 days. CASI focuses on developing innovative therapeutics in China and globally, particularly in hematology oncology. The company aims to leverage its regulatory and commercial expertise in China to enhance its market presence.

CASI Pharmaceuticals has announced that the Chinese Center for Drug Evaluation granted Breakthrough Therapy Designation for its partner Juventas Cell Therapy's CNCT19, a potential CD19 CAR-T therapy for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). This designation is based on initial data from a Phase I study assessing safety and efficacy. Dr. Wei-Wu He highlighted this as a significant regulatory milestone, emphasizing its rarity in China. CASI holds co-commercial rights to CNCT19 and is committed to its development and commercialization.

CASI Pharmaceuticals, Inc. announced the appointment of Weihao Xu as the new Chief Financial Officer on December 16, 2020. Xu, who previously founded a healthcare investment firm and served as CFO for 111, Inc., brings extensive experience in financial operations and corporate strategy. He will report to Dr. Wei-Wu He, Chairman and CEO. The leadership change aims to strengthen CASI's strategic initiatives in 2021 and enhance its focus on innovating therapeutics in hematology and oncology.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) announces that partner Juventas completed a $65 million financing and has initiated the first patient enrollment in a Phase II registration study for CNCT19 (CD19 CAR-T) in China targeting relapsed/refractory B-cell non-Hodgkin lymphoma. CASI's CEO, Dr. Wei-Wu He, views this as a significant milestone and emphasized Juventas' progress in clinical trials. CASI holds a 16% stake in Juventas, highlighting a collaborative co-development and investment strategy aimed at enhancing shareholder returns.

CASI Pharmaceuticals reported Q3 2020 revenues of $4.2 million from EVOMELA, significantly up from $2.7 million year-over-year. The company anticipates full-year revenue to exceed $14 million. R&D expenses grew to $2.8 million, primarily for CID-103's development, while general and administrative costs fell to $5.3 million. The net loss increased to $16.8 million compared to $9.7 million in Q3 2019. Cash and equivalents rose to $74.6 million following a public offering generating $43.7 million.

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) will host a conference call on November 9, 2020, at 4:30 p.m. ET to review its third quarter highlights. The call will provide updates on recent business developments and upcoming milestones. Interested participants can join via phone, with specific numbers for the U.S. and international callers. The Chairman & CEO will lead the discussion, and the call will also be recorded for later replay. CASI focuses on developing and commercializing therapeutics in hematology oncology, primarily in China and the U.S.

BioInvent International AB and CASI Pharmaceuticals have signed an exclusive licensing agreement for the development and commercialization of the anti-FcγRIIB antibody, BI-1206, in Greater China. CASI will handle commercialization, while BioInvent will receive a $5 million upfront payment and could earn up to $83 million in development and commercial milestones, along with royalties on net sales. The agreement includes a $7 million investment in BioInvent shares. BI-1206 is currently under clinical investigation for solid tumors and non-Hodgkin lymphoma.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) has announced that research on CID-103, an anti-CD38 monoclonal antibody, will be presented at the AABB Virtual Annual Meeting from October 3-5, 2020. The presentation, titled 'CID-103: Decreased RBC Binding and Interference with Pretransfusion Test Methods', will take place on October 4, 2020. CID-103 aims to provide enhanced efficacy against malignancies expressing CD38, with Phase 1 trials expected to begin in early 2021. CASI holds exclusive global rights to CID-103.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) has restructured its partnership with Juventas Cell Therapy for the development of CNCT19, an investigational CD19 CAR-T therapy targeting B-cell malignancies. The new agreement reduces CASI's financial exposure while allowing Juventas to attract capital for upcoming trials. CASI will maintain co-commercial rights, receive up to 50% of net profits from CNCT19 sales, and has increased its equity stake in Juventas to 19.65%. The restructuring aims to streamline operations and ensure the successful commercialization of CNCT19.